Latest Triple-negative breast cancer Stories
Cancer drugs of the new, molecular generation destroy malignant breast tumors in a targeted manner: They block characteristic molecules on tumor cells - receptors for the hormones estrogen or progesterone, or a co-receptor, called HER2, that binds to many growth factors.
The spread of breast cancer to distant organs within the body, an event that often leads to death, appears in many cases to involve the loss of a key protein.
Genomic sequencing has revealed therapeutic drug targets for difficult-to-treat, metastatic triple-negative breast cancer (TNBC).
Breast cancers are defined by their drivers – estrogen and progesterone receptors (ER and PR) and HER2 are the most common, and there are drugs targeting each.
The simultaneous inhibition of two separate and seemingly unrelated pathways could potentially provide an effective treatment for women with triple-negative breast cancer.
- Stoppage; cessation (of labor).
- A standing still or idling (of mills, factories, etc.).